Indication
Treatment of adult patients with advanced gastrointestinal stromal tumour (GIST) who have received prior treatment with three or more kinase inhibitors, including imatinib.
Medicine details
- Medicine name:
- ripretinib (Qinlock)
- SMC ID:
- SMC2722
- Pharmaceutical company
- Deciphera Pharmaceuticals
- BNF chapter
- Malignant disease and immunosuppression
- Submission type
- Full
- Publication due date:
- TBC
- SMC meeting date:
- TBC
- Patient group submission deadline:
- 02 December 2024